je.st
news
Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection
2013-09-23 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application for sugammadex sodium injection, Mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or vecuronium. Language: English Contact: Media:Pam Eisele, 908-423-5042orSarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: complete
response
letter
medicine
Category:Biotechnology and Pharmaceuticals